MetaCap

Aprea Therapeutics (APRE) vs Kiora Pharmaceuticals (KPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aprea Therapeutics is the larger company by market cap ($3.2 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%KPRX-71.53%
+6%-35%-75%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%KPRX-71.65%
+4%-36%-75%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus KPRX key metrics
MetricAPREKPRX
Share price$0.229$0.7202
Market cap$3.25M$3.19M
1-day change-53.56%-12.28%
YTD return—-63.44%
1-year return—-61.49%
5-year return—-99.87%
EPS (TTM)$-0.57$-2.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-12.60M$-10.84M
52-week high$1.49$2.91
52-week low$0.2036$0.72
Distance from 52-week high-84.63%-75.25%
Analyst consensusnonenone
Avg. price target upside+1528.82%+1566.20%
Average volume388.67K35.23K
Shares outstanding14.19M4.42M
Employees813
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

APRE vs KPRX FAQ

Which is bigger, Aprea Therapeutics or Kiora Pharmaceuticals?

Aprea Therapeutics (APRE) is larger, with a market capitalization of $3.25M compared with $3.19M for Kiora Pharmaceuticals (KPRX).

Are Aprea Therapeutics and Kiora Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons